Cetrorelixum [Inn-Latin]
Brand names,
Cetrorelixum [Inn-Latin]
Analogs
Cetrorelixum [Inn-Latin]
Brand Names Mixture
Cetrorelixum [Inn-Latin]
Chemical_Formula
No information avaliable
Cetrorelixum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic2/cetrorelix.htm
Cetrorelixum [Inn-Latin]
fda sheet
Cetrorelixum [Inn-Latin]
msds (material safety sheet)
Cetrorelixum [Inn-Latin]
Synthesis Reference
No information avaliable
Cetrorelixum [Inn-Latin]
Molecular Weight
1431.06 g/mol
Cetrorelixum [Inn-Latin]
Melting Point
No information avaliable
Cetrorelixum [Inn-Latin]
H2O Solubility
No information avaliable
Cetrorelixum [Inn-Latin]
State
Solid
Cetrorelixum [Inn-Latin]
LogP
No information avaliable
Cetrorelixum [Inn-Latin]
Dosage Forms
Powder for solution
Cetrorelixum [Inn-Latin]
Indication
For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Cetrorelixum [Inn-Latin]
Pharmacology
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.
Cetrorelixum [Inn-Latin]
Absorption
Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.
Cetrorelixum [Inn-Latin]
side effects and Toxicity
No information avaliable
Cetrorelixum [Inn-Latin]
Patient Information
Cetrorelixum [Inn-Latin]
Organisms Affected
Humans and other mammals